These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9039444)

  • 1. Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis.
    Wallis RS; Helfand MS; Whalen CC; Johnson JL; Mugerwa RD; Vjecha M; Okwera A; Ellner JJ
    Tuber Lung Dis; 1996 Dec; 77(6):516-23. PubMed ID: 9039444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
    Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J
    Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
    J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn P
    Trans R Soc Trop Med Hyg; 1995; 89(1):78-82. PubMed ID: 7747316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis.
    Hanna LE; Nayak K; Subramanyam S; Venkatesan P; Narayanan PR; Swaminathan S
    Indian J Med Res; 2009 May; 129(5):548-54. PubMed ID: 19675383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis.
    Hosp M; Elliott AM; Raynes JG; Mwinga AG; Luo N; Zangerle R; Pobee JO; Wachter H; Dierich MP; McAdam KP; Fuchs D
    Lung; 1997; 175(4):265-75. PubMed ID: 9195554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neopterin levels in HIV infected patients with & without tuberculosis.
    Immanuel C; Victor L; Chelvi KS; Padmapriyadarsini C; Rehman F; Iliayas S; Swaminathan S
    Indian J Med Res; 2005 Apr; 121(4):220-5. PubMed ID: 15817939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.
    Wallis RS; Kyambadde P; Johnson JL; Horter L; Kittle R; Pohle M; Ducar C; Millard M; Mayanja-Kizza H; Whalen C; Okwera A
    AIDS; 2004 Jan; 18(2):257-64. PubMed ID: 15075543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.
    Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
    Mwinga A; Hosp M; Godfrey-Faussett P; Quigley M; Mwaba P; Mugala BN; Nyirenda O; Luo N; Pobee J; Elliott AM; McAdam KP; Porter JD
    AIDS; 1998 Dec; 12(18):2447-57. PubMed ID: 9875583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults.
    Lim HJ; Okwera A; Mayanja-Kizza H; Ellner JJ; Mugerwa RD; Whalen CC
    HIV Clin Trials; 2006; 7(4):172-83. PubMed ID: 17065029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis.
    Palme IB; Gudetta B; Bruchfeld J; Muhe L; Giesecke J
    Pediatr Infect Dis J; 2002 Nov; 21(11):1053-61. PubMed ID: 12442029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis.
    Schwander S; Rüsch-Gerdes S; Mateega A; Lutalo T; Tugume S; Kityo C; Rubaramira R; Mugyenyi P; Okwera A; Mugerwa R
    Tuber Lung Dis; 1995 Jun; 76(3):210-8. PubMed ID: 7548903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum neopterin and serum beta 2-microglobulin in subjects with lung infections.
    Carstens J; Andersen PL
    Eur Respir J; 1994 Jul; 7(7):1233-8. PubMed ID: 7925900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
    Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
    Hawken M; Nunn P; Gathua S; Brindle R; Godfrey-Faussett P; Githui W; Odhiambo J; Batchelor B; Gilks C; Morris J
    Lancet; 1993 Aug; 342(8867):332-7. PubMed ID: 7687729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
    van Gorkom J; Kibuga DK
    Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.